Endothelin-1 stimulates preadipocyte growth via the PKC, STAT3, AMPK, c-JUN, ERK, sphingosine kinase, and sphingomyelinase pathways

Autor: Yi Wei Tsuei, Chih Pin Chuu, Yung Hsi Kao, Yen Yue Lin, Li Jane Shih, Yow Chii Kuo, An Ci Siao
Rok vydání: 2020
Předmět:
0301 basic medicine
MAPK/ERK pathway
Endothelin Receptor Antagonists
STAT3 Transcription Factor
Physiology
Pyridines
Sphingosine kinase
030209 endocrinology & metabolism
p38 Mitogen-Activated Protein Kinases
03 medical and health sciences
Mice
0302 clinical medicine
AMP-activated protein kinase
Piperidines
3T3-L1 Cells
Nitriles
Adipocytes
Butadienes
Animals
Extracellular Signal-Regulated MAP Kinases
Protein kinase B
Protein kinase C
Protein Kinase C
Cell Proliferation
biology
Dose-Response Relationship
Drug

Endothelin-1
Chemistry
Receptors
Endothelin

c-jun
Imidazoles
JNK Mitogen-Activated Protein Kinases
AMPK
Cell Differentiation
Cell Biology
Cell biology
Phosphotransferases (Alcohol Group Acceptor)
030104 developmental biology
Sphingomyelin Phosphodiesterase
Gene Expression Regulation
Mitogen-activated protein kinase
biology.protein
Oligopeptides
Signal Transduction
Zdroj: American journal of physiology. Cell physiology. 319(5)
ISSN: 1522-1563
Popis: Endothelin (ET)-1 regulates adipogenesis and the endocrine activity of fat cells. However, relatively little is known about the ET-1 signaling pathway in preadipocyte growth. We used 3T3-L1 preadipocytes to investigate the signaling pathways involved in ET-1 modulation of preadipocyte proliferation. As indicated by an increased number of cells and greater incorporation of bromodeoxyuridine (BrdU), the stimulation of preadipocyte growth by ET-1 depends on concentration and timing. The concentration of ET-1 that increased preadipocyte number by 51–67% was ~100 nM for ~24–48 h of treatment. ET-1 signaling time dependently stimulated phosphorylation of ERK, c-JUN, STAT3, AMPK, and PKCα/βII proteins but not AKT, JNK, or p38 MAPK. Treatment with an ETAR antagonist, such as BQ610, but not ETBR antagonist BQ788, blocked the ET-1-induced increase in cell proliferation and phosphorylated levels of ERK, c-JUN, STAT3, AMPK, and PKCα/βII proteins. In addition, pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), JAK2/STAT3 (AG490), AMPK (compound C), or PKC (Ro318220) prevented the ET-1-induced increase in cell proliferation and reduced the ET-1-stimulated phosphorylation of ERK1/2, c-JUN, STAT3, AMPK, and PKCα/β. Moreover, the SphK antagonist suppressed ET-1-induced cell proliferation and ERK, c-JUN, STAT3, AMPK, and PKC phosphorylation, and the SMase2 antagonist suppressed ET-1-induced cell proliferation. However, neither the p38 MAPK antagonist nor the CerS inhibitor altered the effect of ET-1. The results indicate that ETAR, JAK2/STAT3, ERK1/2, JNK/c-JUN, AMPK, PKC, SphK, and SMase2, but not ETBR, p38 MAPK, or CerS, are necessary for the ET-1 stimulation of preadipocyte proliferation.
Databáze: OpenAIRE